# BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.**

```
=> d his

     (FILE 'HOME' ENTERED AT 11:15:07 ON 31 JAN 2003)

     FILE 'REGISTRY' ENTERED AT 11:15:12 ON 31 JAN 2003
L1             STRUCTURE UPLOADED
L2             QUE L1
L3           6 S L2
L4         107 S L2 SSS FUL

     FILE 'CAPLUS' ENTERED AT 11:15:56 ON 31 JAN 2003
L5          25 S L4

     FILE 'REGISTRY' ENTERED AT 11:16:42 ON 31 JAN 2003
L6             STRUCTURE UPLOADED
L7             QUE L6
L8           3 S L7  SUB=L4 SAM
L9          86 S L7  SUB=L4 FUL

     FILE 'CAPLUS' ENTERED AT 11:17:57 ON 31 JAN 2003
L10          9 S L9

=> d bib abs hitstr 1-9
```

L10 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 2002:503385 CAPLUS
DN 137:63263
TI Preparation of diazabicycloalkanes as CNS-penetrant .alpha.7 nicotinic receptor agonists.
IN Coe, Jotham Wadsworth; O'Donnell, Christopher John; O'Neill, Brian Thomas
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI EP 1219622 | A2 | 20020703 | EP 2001-310270 | 20011207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| US 2002086871 | A1 | 20020704 | US 2001-47850 | 20011023 |
| BR 2001006462 | A | 20020924 | BR 2001-6462 | 20011228 |
| PRAI US 2000-258736P | P | 20001229 | | |

OS MARPAT 137:63263
GI



I

AB Title compds. [I; m, n, o = 1-2; A = O, S, NR1; B = N, CR2; Q = N, CR3; D = N, CR4; E = N, CR5; R1 = H, alkyl, CO2R6, CH2R6, CONR6R7, COR6, SO2R6; R2-R5 = F, Cl, Br, iodo, NO2, cyano, CF3, NR6R7, NR6COR7, NR6CONR7R8, NR6CO2R7, NR6SO2R7, NR6SO2NR7R8, OR6, O2CR6, OCO2R6, O2CNR6R7, O2CSR6, CO2R6, COR6, CONR6R7, SR6, SOR6, SO2R6, SO2NR6R7, R6; R6-R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, bicycloalkyl, bicycloalkenyl, heterobicycloalkyl, heterobicycloalkenyl, aryl, heteroaryl; R6-R8 are optionally substituted with 1-6 F, Cl, Br, iodo, NO2, cyano, CF3, NR9R10, NR9COR10, NR9CONR10R11, NR9CO2R10, NR9SO2R10, NR9SO2NR101R11, OR9, O2CR9, O2COR9, O2CNR9R10, O2CSR9, CO2R9, COR9, CONR9R10, SR9, SOR9, SO2R9, SO2NR9R10, R9; R9-R11 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, bicycloalkyl, bicycloalkenyl, heterobicycloalkyl, heterobicycloalkenyl, aryl, heteroaryl; R9-R11 is optionally substituted with 1-6 F, Cl, Br, iodo, NO2, cyano, CF3, NR12R13, NR12COR13, NR12CONR13R14, NR12CO2R13, NR12SO2R13, NR12SO2NR13R14, OR12, O2CR12, O2COR12, OCONR12R13, O2CSR12, CO2R12, COR12, CONR12R13, SR12, SOR12, SO2R12, SO2NR12R13, R12; R12-R14 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, bicycloalkyl, bicycloalkenyl, heterobicycloalkyl, heterobicycloalkenyl, aryl, heteroaryl; R2R3, R3R4, R4R5 may form a 6-membered arom. or heteroarom. ring], were prepd. Thus, 2-chlorobenzoxazole and 1,4-diazabicyclo[3.2.2]nonane were stirred in MeOH at 0.degree. to room temp.; after 16 h (Me2CH)2NEt was added and the mixt. was stirred a further 4.5 h to give 35% 4-benzoxazol-2-yl-1,4-bicyclo[3.2.2]nonane. In

an assay involving [125I]-bungarotoxin binding to nicotinic receptors in GH4Cl cells, I showed IC50<10 .mu.M.

IT **376354-12-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of diazabicycloalkanes as CNS-penetrant .alpha.7 nicotinic receptor agonists)
RN 376354-12-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-nitro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



IT **376354-15-3P 376354-23-3P 439607-89-3P**
**439607-90-6P 439607-94-0P 439607-96-2P**
**439607-97-3P 439607-98-4P 439607-99-5P**
**439608-00-1P 439608-07-8P 439608-09-0P**
**439608-10-3P 439608-11-4P 439608-13-6P**
**439608-14-7P 439608-15-8P 439608-16-9P**
**439608-17-0P 439608-18-1P 439608-19-2P**
**439608-20-5P 439608-22-7P 439608-36-3P**
**439608-37-4P 439608-39-6P 439608-40-9P**
**439608-41-0P 439608-42-1P 439608-43-2P**
**439608-44-3P 439608-50-1P 439608-52-3P**
**439608-53-4P 439608-54-5P 439608-56-7P**
**439608-57-8P 439608-58-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of diazabicycloalkanes as CNS-penetrant .alpha.7 nicotinic receptor agonists)
RN 376354-15-3 CAPLUS
CN 5-Benzoxazolamine, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)- (9CI) (CA INDEX NAME)



RN 376354-23-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439607-89-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-phenyl-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439607-90-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-bromo-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439607-94-0 CAPLUS
CN Naphth[1,2-d]oxazole, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)- (9CI) (CA INDEX NAME)



RN 439607-96-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(6-phenyl-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439607-97-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-chloro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439607-98-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-fluoro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439607-99-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(6-nitro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-00-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-iodo-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-07-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[5-(3-pyridinyl)-2-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 439608-09-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(4-nitro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-10-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-methyl-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-11-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(6-methyl-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-13-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(6-chloro-5-nitro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-14-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5,7-dichloro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-15-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-chloro-6-nitro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 439608-16-9 CAPLUS
CN 5-Benzoxazolamine, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 439608-17-0 CAPLUS
CN 5-Benzoxazolamine, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)-N-[(2E)-3-phenyl-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 439608-18-1 CAPLUS
CN 5-Benzoxazolamine, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 439608-19-2 CAPLUS
CN 5-Benzoxazolamine, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 439608-20-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[5-(3-methylphenyl)-2-benzoxazolyl]-

(9CI) (CA INDEX NAME)



RN 439608-22-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[5-[4-(trifluoromethyl)phenyl]-2-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 439608-36-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-phenyl-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-37-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-bromo-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-39-6 CAPLUS
CN Naphth[1,2-d]oxazole, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-40-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(6-phenyl-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-41-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-chloro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-42-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-fluoro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-43-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(6-nitro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-44-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-iodo-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-50-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-[5-(3-pyridinyl)-2-benzoxazolyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-52-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(4-nitro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-53-4 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-nitro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-54-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-methyl-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-56-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(6-chloro-5-nitro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-57-8 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5,7-dichloro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 439608-58-9 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-chloro-6-nitro-2-benzoxazolyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT **439607-92-8P 439608-38-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of diazabicycloalkanes as CNS-penetrant .alpha.7 nicotinic receptor agonists)
RN 439607-92-8 CAPLUS
CN Naphth[2,3-d]oxazole, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)- (9CI) (CA INDEX NAME)



RN 439608-38-5 CAPLUS
CN Naphth[2,3-d]oxazole, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

L10 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 2001:886122 CAPLUS
DN 136:6021
TI 1,4-Diazabicyclo[3.2.2]nonylbenzoxazole, -benzothiazole and -benzimidazole derivatives as selective nicotinic .alpha.7 antagonists
IN Galli, Frederic; Lochead, Alistair; Samson, Axelle
PA Sanofi-Synthelabo, Fr.
SO PCT Int. Appl., 19 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2001092261 | A1 | 20011206 | WO 2001-FR1651 | 20010529 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | FR 2809730 | A1 | 20011207 | FR 2000-6975 | 20000531 |
| | FR 2809730 | B1 | 20020719 | | |
| PRAI | FR 2000-6975 | A | 20000531 | | |

OS MARPAT 136:6021
GI




I

AB Title compds. I [X = O, S, NH; R1-R4 = H, halogen, NO2, amino, CF3, trifluoroalkoxy, CN, OH, alkyl, alkoxy, Ph] were prepd. for use as selctive nicotinic .alpha.7 antagonists with IC50 0.021-0.125 .mu.M. Thus, 1,4-diazabicyclo[3.2.2]nonane was treated with 2-chlorobenzoxazole to give I [X = O, R1-R4 = H].

IT **376354-12-0P 376354-23-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 1,4-diazabicyclo[3.2.2]nonylbenzoxazole, -benzothiazole and -benzimidazole derivs. as selective nicotinic .alpha.7 antagonists)

RN 376354-12-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-nitro-2-benzoxazolyl)- (9CI) (CA INDEX NAME)



RN 376354-23-3 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzoxazolyl)- (9CI) (CA INDEX NAME)



IT **376354-09-5P 376354-15-3P 376354-18-6P**
**376354-19-7P 376354-20-0P 376354-21-1P**
**376354-22-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1,4-diazabicyclo[3.2.2]nonylbenzoxazole, -benzothiazole and -benzimidazole derivs. as selective nicotinic .alpha.7 antagonists)
RN 376354-09-5 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(2-benzoxazolyl)-, dihydrobromide (9CI) (CA INDEX NAME)



●2 HBr

RN 376354-15-3 CAPLUS
CN 5-Benzoxazolamine, 2-(1,4-diazabicyclo[3.2.2]non-4-yl)- (9CI) (CA INDEX NAME)



RN 376354-18-6 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(4-methyl-2-benzoxazolyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 376354-19-7 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-methyl-2-benzoxazolyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 376354-20-0 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-methyl-2-benzoxazolyl)-, dihydrobromide (9CI) (CA INDEX NAME)




●2 HBr

RN 376354-21-1 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-phenyl-2-benzoxazolyl)-, dihydrobromide (9CI) (CA INDEX NAME)




●2 HBr

RN 376354-22-2 CAPLUS
CN 1,4-Diazabicyclo[3.2.2]nonane, 4-(5-chloro-2-benzoxazolyl)-, dihydrobromide (9CI) (CA INDEX NAME)




●2 HBr

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

applicants

L10 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 2000:368353 CAPLUS
DN 133:4649
TI Preparation of benzoxazole derivatives for treatment of irritable bowel syndrome, functional disorders of the digestive tract, and diarrhea
IN Shiokawa, Sojiro; Sato, Yasuo; Izumi, Masaaki; Yoshida, Satoshi; Murakami, Hiroshi; Ito, Tomoko; Niisato, Tetsutaro
PA Meiji Seika Kaisha, Ltd., Japan
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000031073 | A1 | 20000602 | WO 1999-JP6491 | 19991119 |
| | W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | EP 1134220 | A1 | 20010919 | EP 1999-972633 | 19991119 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | BR 9916793 | A | 20011113 | BR 1999-16793 | 19991119 |
| | AU 753797 | B2 | 20021031 | AU 2000-11850 | 19991119 |
| | NO 2001002443 | A | 20010712 | NO 2001-2443 | 20010518 |
| PRAI | JP 1998-331274 | A | 19981120 | | |
| | WO 1999-JP6491 | W | 19991119 | | |

OS MARPAT 133:4649
GI




I

AB The title compds. I [R1 represents halogeno; R2 represents hydrogen or lower alkyl; and R3 represents hydrogen, lower alkyl, lower alkoxy, hydroxy(lower alkyl), halogeno or amino optionally having a substituent selected from the group consisting of lower alkyl, lower alkenyl, lower alkylcarbony and amino-protective groups] are prepd. 5-Chloro-2-(1-homopiperazinyl)-7-methylbenzoxazole hydrochloride showed ED50 of 0.00025

mg/kg against stress-induced diarrhea in rats. Formulations are given.

IT **270917-08-3P 270917-09-4P 270917-10-7P**
**270917-11-8P 270917-12-9P 270917-13-0P**
**270917-14-1P 270917-15-2P 270917-16-3P**
**270917-17-4P 270917-18-5P 270917-19-6P**
**270917-20-9P 270917-21-0P 270917-22-1P**
**270917-23-2P 270917-24-3P 270917-25-4P**
**270917-26-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxazole derivs. for treatment of irritable bowel syndrome, functional disorders of digestive tract, and diarrhea)

RN 270917-08-3 CAPLUS

CN Benzoxazole, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-methyl- (9CI) (CA INDEX NAME)




RN 270917-09-4 CAPLUS

CN Benzoxazole, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 270917-10-7 CAPLUS

CN Benzoxazole, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-methyl-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 270917-08-3
CMF C13 H16 Cl N3 O



CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 270917-11-8 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-methyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 270917-08-3
CMF C13 H16 Cl N3 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 270917-12-9 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 270917-13-0 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-6-methyl- (9CI) (CA INDEX NAME)




RN 270917-14-1 CAPLUS
CN Benzoxazole, 5-chloro-7-ethyl-2-(hexahydro-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)




RN 270917-15-2 CAPLUS
CN 7-Benzoxazolemethanol, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)




RN 270917-16-3 CAPLUS
CN Acetamide, N-[5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-benzoxazolyl]- (9CI) (CA INDEX NAME)



RN 270917-17-4 CAPLUS
CN Carbamic acid, [5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-benzoxazolyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 270917-18-5 CAPLUS
CN 7-Benzoxazolamine, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 270917-19-6 CAPLUS
CN Benzoxazole, 5,7-dichloro-2-(hexahydro-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 270917-20-9 CAPLUS
CN Benzoxazole, 5,7-dichloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-6-methyl- (9CI) (CA INDEX NAME)



RN 270917-21-0 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-6,7-dimethyl-(9CI) (CA INDEX NAME)



RN 270917-22-1 CAPLUS
CN 7-Benzoxazolamine, 5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 270917-23-2 CAPLUS
CN 7-Benzoxazolamine, 5-chloro-N-ethyl-2-(hexahydro-1H-1,4-diazepin-1-yl)-(9CI) (CA INDEX NAME)



RN 270917-24-3 CAPLUS
CN Methanesulfonamide, N-[5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-benzoxazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 270917-25-4 CAPLUS
CN Benzamide, N-[5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-benzoxazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 270917-26-5 CAPLUS
CN Propanamide, N-[5-chloro-2-(hexahydro-1H-1,4-diazepin-1-yl)-7-benzoxazolyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **270917-33-4P 270917-34-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzoxazole derivs. for treatment of irritable bowel syndrome, functional disorders of digestive tract, and diarrhea)

RN 270917-33-4 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, 4-(7-amino-5-chloro-2-benzoxazolyl)hexahydro-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 270917-34-5 CAPLUS
CN 1H-1,4-Diazepine-1-carboxylic acid, 4-(7-amino-5-chloro-2-benzoxazolyl)hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1998:450896 CAPLUS
DN 129:170108
TI Benzoxazole Derivatives as Novel 5-HT3 Receptor Partial Agonists in the Gut
AU Sato, Yasuo; Yamada, Megumi; Yoshida, Satoshi; Soneda, Tomoko; Ishikawa, Midori; Nizato, Tetsutaro; Suzuki, Kokichi; Konno, Fukio
CS Pharmaceutical Research Center, Meiji Seika Kaisha, Yokohama, 222, Japan
SO Journal of Medicinal Chemistry (1998), 41(16), 3015-3021
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 129:170108
GI




I

AB A series of benzoxazoles with a nitrogen-contg. heterocyclic substituent at the 2-position was prepd. and evaluated for 5-HT3 partial agonist activity on isolated guinea pig ileum. The nature of the substituent at the 5-position of the benzoxazole ring affected the potency for the 5-HT3 receptor, and the 5-chloro derivs. showed increased potency and lowered intrinsic activity. 5-Chloro-7-methyl-2-(4-methyl-1-homopiperazinyl)benzoxazole (I) exhibited a high binding affinity in the same range as that of the 5-HT3 antagonist granisetron, and its intrinsic activity was 12% of that of 5-HT. I inhibited 5-HT-evoked diarrhea but did not prolong the transition time of glass beads in the normal distal colon even at a dose of 100 times the ED50 for diarrhea inhibition in mice. Compds. of this type are expected to be effective for the treatment of irritable bowel syndrome without the side effect of constipation.

IT **159731-51-8P 199292-98-3P 199293-03-3P,**
5-Chloro-2-(4-methyl-1-homopiperazinyl)benzoxazole
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(benzoxazole derivs. as novel 5-HT3 receptor partial agonists in gut in relation to treatment of irritable bowel syndrome)

RN 159731-51-8 CAPLUS
CN Benzoxazole, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)




RN 199292-98-3 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-7-methyl- (9CI) (CA INDEX NAME)




RN 199293-03-3 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1997:744000 CAPLUS
DN 128:22896
TI Preparation of benzoxazoles as serotonin 5-HT3 receptor partial activator
IN Sato, Yasuo; Yamada, Megumi; Kobayashi, Kazuko; Iwamatsu, Katsuyoshi; Konno, Fukio; Shudo, Koichi
PA Meiji Seika Kaisha Ltd., Japan; Shudo, Koichi
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 806419 | A1 | 19971112 | EP 1997-107580 | 19970507 |
| | R: BE, DE, ES, FR, GB, IT, NL, SE | | | | |
| | JP 10029987 | A2 | 19980203 | JP 1997-93821 | 19970411 |
| | US 6037342 | A | 20000314 | US 1997-852747 | 19970506 |
| | US 6297246 | B1 | 20011002 | US 1999-298952 | 19990426 |
| | US 6333328 | B1 | 20011225 | US 2000-686759 | 20001012 |
| | US 2001016579 | A1 | 20010823 | US 2001-796805 | 20010302 |
| | US 2003013730 | A1 | 20030116 | US 2002-219496 | 20020816 |
| PRAI | JP 1996-115008 | A | 19960509 | | |
| | JP 1997-93821 | A | 19970411 | | |
| | US 1997-852747 | A3 | 19970506 | | |
| | US 1999-298952 | A3 | 19990426 | | |
| | US 2000-686759 | A3 | 20001012 | | |
| | US 2001-796805 | A3 | 20010302 | | |

OS MARPAT 128:22896
GI




I

AB The title compds. [I; R1-R4 = H, halo, lower alkyl, etc.; Y = (un)satd. (un)substituted 4-8 membered heterocycle contg. 1-3 N atoms] which are serotonin 5-HT3 receptor partial activators, in addn. to its serotonin 5-HT3 receptor antagonism, and do not cause constipation as a side effect, were prepd. and formulated. Thus, treatment of 5-chloro-2-mercaptobenzoxazole with PCl5 in C6H6 followed by addn. of 1-methylpiperazine afforded I [R1 = R3 = R4 = H; R2 = Cl; Y = 4-Me-piperazinyl] which showed activation of 0.55 i.a. (i.a. value was expressed as the ratio of the max. reaction of the compd. when the max. contraction reaction obtained by 10 .mu.M of serotonin 5-HT was defined as 1).

IT **199292-96-1P 199292-97-2P 199292-98-3P**
**199292-99-4P 199293-00-0P 199293-01-1P**
**199293-03-3P 199293-04-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzoxazoles as serotonin 5-HT3 receptor partial activator)

RN 199292-96-1 CAPLUS
CN Benzoxazole, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-5-methyl- (9CI) (CA INDEX NAME)




RN 199292-97-2 CAPLUS
CN Benzoxazole, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-5,7-dimethyl- (9CI) (CA INDEX NAME)




RN 199292-98-3 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-7-methyl- (9CI) (CA INDEX NAME)




RN 199292-99-4 CAPLUS
CN Benzoxazole, 5-chloro-7-ethyl-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 199293-00-0 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6-methyl- (9CI) (CA INDEX NAME)



RN 199293-01-1 CAPLUS
CN Naphth[1,2-d]oxazole, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 199293-03-3 CAPLUS
CN Benzoxazole, 5-chloro-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 199293-04-4 CAPLUS
CN 6-Benzoxazolamine, 5-chloro-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



IT **199293-14-6**
RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of benzoxazoles as serotonin 5-HT3 receptor partial activator)

RN 199293-14-6 CAPLUS

CN Benzoxazole, 5-chloro-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-6-nitro- (9CI) (CA INDEX NAME)



L10 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1996:294873 CAPLUS
DN 124:343286
TI Preparation of (benzoxazolyl)- and (benzothiazolyl)oxazolidinone antibiotics
IN Haebisch, Dieter; Riedl, Bernd; Ruppelt, Martin; Stolle, Andreas; Wild, Hanno; Endermann, Rainer; Bremm, Klaus-Dieter; Kroll, Hein-Peter; Labischinski, Harald; et al.
PA Bayer A.-G., Germany
SO Ger. Offen., 71 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | DE 19514313 | A1 | 19960208 | DE 1995-19514313 | 19950418 |
| | RO 115263 | B1 | 19991230 | RO 1995-1322 | 19950718 |
| | EP 697412 | A1 | 19960221 | EP 1995-111477 | 19950721 |
| | EP 697412 | B1 | 20000112 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | AT 188698 | E | 20000115 | AT 1995-111477 | 19950721 |
| | AU 9527230 | A1 | 19960215 | AU 1995-27230 | 19950727 |
| | AU 698939 | B2 | 19981112 | | |
| | US 5529998 | A | 19960625 | US 1995-508245 | 19950727 |
| | JP 08081463 | A2 | 19960326 | JP 1995-211265 | 19950728 |
| | IL 114784 | A1 | 19991028 | IL 1995-114784 | 19950731 |
| | FI 9503665 | A | 19960204 | FI 1995-3665 | 19950801 |
| | NO 9503045 | A | 19960205 | NO 1995-3045 | 19950802 |
| | ZA 9506445 | A | 19960322 | ZA 1995-6445 | 19950802 |
| | HU 75037 | A2 | 19970328 | HU 1995-2295 | 19950802 |
| | CN 1122803 | A | 19960522 | CN 1995-115330 | 19950803 |
| PRAI | DE 1994-4427475 | A1 | 19940803 | | |
| | DE 1995-19514313 | A | 19950418 | | |

OS MARPAT 124:343286
GI




I




II

AB The title compds. [I; A = O, S(O)a; a = 0, 2; G, L, M = H, CO2H, halogen, CN, CHO, CF3, NO2, (un)branched alkoxy, etc.; R1 = OSO2R3, tertiary-amino group; R3 = (un)substituted alkyl, (un)substituted Ph; R2 = H, CHO, CO2H, alkoxycarbonyl, etc.; * = chiral C], useful in pharmaceuticals, esp. as antibiotics, are prepd. Thus, benzothiazole II, m.p. 228.degree., was prepd. by the m-chloroperbenzoic acid oxidn. of the methylthio analog, and demonstrated a MIC against Staph. 133 (sic) of 1 .mu.g/mL and Staph. 48N (sic) of 2 mg/mL.

IT **176491-30-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (benzoxazolyl)- and (benzothiazolyl)oxazolidinone antibiotics)

RN 176491-30-8 CAPLUS

CN Acetamide, N-[[3-[2-(hexahydro-1H-1,4-diazepin-1-yl)-6-benzoxazolyl]-2-oxo-5-oxazolidinyl]methyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1995:434437 CAPLUS
DN 123:33040
TI Synthesis of new armed cyclopolyamines and their selective extraction properties for metal ions
AU matsumoto, Kiyoshi; Fukuyama, Keisuke; Iida, Hirokazu; Toda, Mitsuo; Lown, J. William
CS Grad. Sch. Human Environ. Studies, Kyoto Univ., Kyoto, 606-01, Japan
SO Heterocycles (1995), 41(2), 237-44
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 123:33040
GI



I

AB A variety of new armed cyclopolyamines, e.g. I (R = 2-pyridyl), were prepd. by high pressure SNAr reactions (0.8 GPa, 100.degree.C) of cyclopolyamines with heteroarom. halides. Certain of these agents show selective extn. properties for Hg2+ and Ag+ ions.

IT **131119-38-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of cyclopolyamines and their selective extn. properties for metal ions)

RN 131119-38-5 CAPLUS
CN Benzoxazole, 2,2'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis- (9CI) (CA INDEX NAME)



L10 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1995:252545 CAPLUS
DN 122:31567
TI Preparation of piperazinylbenzoxazoles as serotonin 5-HT3 receptor antagonists.
IN Iwamatsu, Katsuyoshi; Sato, Yasuo; Amano, Kazuko; Izumi, Masaaki; Konno, Fukio; Shibahara, Seiji; Inoye, Shigeharu; Shudo, Koichi
PA Meiji Seika Kaisha Ltd., Japan
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 621271 | A1 | 19941026 | EP 1994-105997 | 19940418 |
| | EP 621271 | B1 | 20011017 | | |
| | R: DE, ES, FR, GB, IT, NL, SE | | | | |
| | JP 06345744 | A2 | 19941220 | JP 1994-42909 | 19940314 |
| | JP 3193560 | B2 | 20010730 | | |
| | ES 2165859 | T3 | 20020401 | ES 1994-105997 | 19940418 |
| | US 5631257 | A | 19970520 | US 1995-487697 | 19950607 |
| PRAI | JP 1993-90086 | A | 19930416 | | |
| | JP 1994-42909 | A | 19940314 | | |
| | US 1994-228894 | B1 | 19940418 | | |

OS MARPAT 122:31567
GI





AB Title compds. I (R1, R2, R3, R4 = H, alkyl, alkenyl each of which may be substituted, halo, HO, H2N, alkoxy, HO2C, H2NCO, O2N; any 2 of R1-R4 may form a 3-7-membered aryl or heterocyclyl; R5 = alkyl, alkenyl, aralkyl each of which may be substituted; m, n = 1-3) and II (R6 = alkyl, alkenyl, aralkyl each of which may be substituted; R5R6 = 3-7-membered heterocyclyl; X- = anion) are prepd. 2-Chlorobenzoxazole and N-methylpiperazine were reacted to give I (R1-4 = H, R5 = Me, m = n = 2) which was treated with H2C:CHCH2I to give II (R1-4 = H, R5 = Me, R6 = ally, m = n = 2, X- = I) which at 0.3 mg/kg showed 5-HT3 receptor antagonism 82% inhibitory ratio.

IT **159731-51-8P 159731-52-9P 159731-53-0P**
**159731-54-1P 159731-55-2P 159731-56-3P**
**159731-57-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazinylbenzoxazoles as serotonin 5-HT3 receptor antagonists.)

RN 159731-51-8 CAPLUS
CN Benzoxazole, 2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 159731-52-9 CAPLUS
CN 1H-1,4-Diazepinium, 4-(2-benzoxazolyl)hexahydro-1,1-dimethyl-, iodide (9CI) (CA INDEX NAME)



● $I^-$

RN 159731-53-0 CAPLUS
CN 1H-1,4-Diazepinium, 4-(2-benzoxazolyl)hexahydro-1-methyl-1-(2-propenyl)-, iodide (9CI) (CA INDEX NAME)



● $I^-$

RN 159731-54-1 CAPLUS
CN 1H-1,4-Diazepinium, 4-(2-benzoxazolyl)hexahydro-1-(2-hydroxyethyl)-1-methyl-, iodide (9CI) (CA INDEX NAME)



● $I^-$

RN 159731-55-2 CAPLUS
CN Benzoxazole, 2-(hexahydro-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)



RN 159731-56-3 CAPLUS
CN 8-Aza-5-azoniaspiro[4.6]undecane, 8-(2-benzoxazolyl)-, iodide (9CI) (CA INDEX NAME)



● $I^-$

RN 159731-57-4 CAPLUS
CN 1H-1,4-Diazepine-1-ethanol, 4-(2-benzoxazolyl)hexahydro- (9CI) (CA INDEX NAME)



L10 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1991:23936 CAPLUS
DN 114:23936
TI Synthesis of double-armed azaoligocycles based upon high pressure aromatic nucleophilic substitution reactions
AU Matsumoto, Kiyoshi; Minatogawa, Hiroyuki; Toda, Mitsuo; Munakata, Megumu
CS Coll. Liberal Arts Sci., Kyoto Univ., Kyoto, 606, Japan
SO Heterocycles (1990), 31(7), 1217-20
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English
OS CASREACT 114:23936
GI




I

AB A variety of title compds., e.g., I ( R = pyridin-2-yl, 2-thiazolyl, 2-pyrimidinyl) were prepd. through high pressure SNAr reactions (0.8 GPa, 100.degree.) of homopiperazine I (R = H) with 5- and 6-membered heteroarom. halides, e.g., 2-fluoropyridine, 2-bromothiazole, the yields being good to excellent when the halides are activated by electronic effects.

IT **131119-38-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 131119-38-5 CAPLUS
CN Benzoxazole, 2,2'-(tetrahydro-1H-1,4-diazepine-1,4(5H)-diyl)bis- (9CI) (CA INDEX NAME)



C:\STNEXP4\QUERIES\09856372.str













ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
ring bonds :
1-2 1-7 2-3 3-4 4-5 5-6 6-7 8-9 8-13 9-10 10-11 11-12 12-13
12-14 13-16 14-15 15-16
exact/norm bonds :
1-2 1-7 2-3 3-4 4-5 5-6 6-7 12-14 13-16 14-15 15-16
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

C:\STNEXP4\QUERIES\09856372.str





ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
3-15
ring bonds :
1-2 1-7 2-3 3-4 4-5 5-6 6-7 8-9 8-13 9-10 10-11 11-12 12-13
12-14 13-16 14-15 15-16
exact/norm bonds :
1-2 1-7 2-3 3-4 3-15 4-5 5-6 6-7 12-14 13-16 14-15 15-16
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom